KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Biomarin Pharmaceutical's Total Non-Current Liabilities rose 647.31% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 647.31%. This contributed to the annual value of $1.2 billion for FY2024, which is 3208.78% down from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Total Non-Current Liabilities stood at $1.4 billion, which was up 647.31% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Total Non-Current Liabilities registered a high of $1.8 billion during Q4 2023, and its lowest value of $1.2 billion during Q4 2024.
  • For the 5-year period, Biomarin Pharmaceutical's Total Non-Current Liabilities averaged around $1.5 billion, with its median value being $1.6 billion (2022).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Total Non-Current Liabilities soared by 1308.15% in 2021 and then crashed by 3208.78% in 2024.
  • Biomarin Pharmaceutical's Total Non-Current Liabilities (Quarter) stood at $1.6 billion in 2021, then rose by 1.9% to $1.7 billion in 2022, then rose by 5.87% to $1.8 billion in 2023, then plummeted by 32.09% to $1.2 billion in 2024, then increased by 16.05% to $1.4 billion in 2025.
  • Its Total Non-Current Liabilities stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.2 billion for Q1 2025.